Literature DB >> 10069186

Comparative cytotoxicity of ionic and non-ionic radiocontrast agents on MDCK cell monolayers in vitro.

C S Schick1, C Haller.   

Abstract

BACKGROUND: Intravascular radiocontrast agents may cause acute renal failure, particularly in patients with pre-existing renal insufficiency. Direct cytotoxic effects of radiocontrast agents on renal tubular cells may contribute to the pathogenesis of radiocontrast-induced nephropathy.
METHODS: We analysed the cytotoxicity of the ionic radiocontrast agents diatrizoate (monomeric) and ioxaglate (dimeric), as well as of the non-ionic radiocontrast agents iohexol (monomeric) and iodixanol (dimeric) on the renal epithelial Madin Darby Canine Kidney (MDCK) cell line grown on permeable supports. The toxicity assays assessed cell viability, transmonolayer resistance and inulin permeability between the apical and basal cell culture compartment. In addition, the distribution of the tight-junction-associated membrane proteins ZO-1 and occludin was analysed using immunofluorescence microscopy.
RESULTS: In all assays the high osmolal ionic compound diatrizoate had significant cytotoxic effects that included the partial redistribution of the tight-junction-associated membrane proteins into a cytoplasmic compartment. To a lesser extent this redistribution also occurred with the dimeric ionic compound ioxaglate, but not with the non-ionic radiocontrast agents. With regards to cell viability, transmonolayer resistance and inulin permeability the radiocontrast agents with reduced osmolality were significantly less toxic than diatrizoate, independent of their ionic strength.
CONCLUSIONS: Physicochemical factors contribute to the cytotoxicity of radiocontrast agents in vitro. The redistribution of tight-junction-associated membrane proteins by the ionic radiocontrast agents corresponds with the loss of the barrier function of the epithelial cell monolayer, which is a major pathophysiological mechanism in acute renal failure. The radiocontrast agents with reduced osmolality are less cytotoxic than diatrizoate, independent of their ionicity. Hyperosmolality appears to be a more important determinant of the cytotoxicity of diatrizoate than ionic strength.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069186     DOI: 10.1093/ndt/14.2.342

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

Review 1.  Cell adhesion molecules in chemically-induced renal injury.

Authors:  Walter C Prozialeck; Joshua R Edwards
Journal:  Pharmacol Ther       Date:  2007-01-23       Impact factor: 12.310

Review 2.  Contrast-induced nephropathy: pathogenesis and prevention.

Authors:  Robert E Cronin
Journal:  Pediatr Nephrol       Date:  2009-05-15       Impact factor: 3.714

3.  Cytotoxic Effects of Nonionic Iodinated Contrast Agent on Human Adipose-Derived Mesenchymal Stem Cells.

Authors:  Tao Wu; Hai Nie; Allan B Dietz; David R Salek; Jay Smith; Andre J van Wijnen; Wenchun Qu
Journal:  PM R       Date:  2018-06-01       Impact factor: 2.298

4.  Cytotoxicity of local anesthetics and nonionic contrast agents on bovine intervertebral disc cells cultured in a three-dimensional culture system.

Authors:  Ana V Chee; Jing Ren; Brett A Lenart; Er-Yun Chen; Yejia Zhang; Howard S An
Journal:  Spine J       Date:  2013-11-15       Impact factor: 4.166

Review 5.  Histopathological Evaluation of Contrast-Induced Acute Kidney Injury Rodent Models.

Authors:  Norbert Kiss; Péter Hamar
Journal:  Biomed Res Int       Date:  2016-11-16       Impact factor: 3.411

Review 6.  Contrast-induced acute kidney injury: A review of practical points.

Authors:  Sercin Ozkok; Abdullah Ozkok
Journal:  World J Nephrol       Date:  2017-05-06

Review 7.  Promising novel therapy with hydrogen gas for emergency and critical care medicine.

Authors:  Motoaki Sano; Masaru Suzuki; Koichiro Homma; Kei Hayashida; Tomoyoshi Tamura; Tadashi Matsuoka; Yoshinori Katsumata; Shuko Onuki; Junichi Sasaki
Journal:  Acute Med Surg       Date:  2017-10-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.